Boston Scientific Alerts Recall of AXIOS Stents Amid 167 Serious Injuries
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
- Recall Notification: Boston Scientific issued a recall notice on December 19, 2025, instructing customers to immediately halt the use and distribution of certain AXIOS stents and electrocautery-enhanced delivery systems due to high-risk concerns during procedures, potentially damaging the company's reputation and market trust.
- Safety Hazard Reports: As of December 23, Boston Scientific reported 167 serious injuries and three deaths associated with the issue, indicating difficulties in stent deployment and expansion that may extend procedure times and require additional interventions, thus increasing healthcare costs.
- Institutional Response Measures: The company instructed healthcare facilities to remove affected products from inventory and store them securely, while also requiring hospital systems to notify other facilities within their networks to ensure visibility of the alert for all users and handlers, thereby mitigating potential risks.
- Regulatory Review Updates: The FDA is actively reviewing information related to this potentially high-risk device issue and has committed to providing updates as significant new details become available, reflecting the regulatory body's heightened focus on medical device safety.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BSX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.790
Low
112.00
Averages
125.74
High
140.00
Current: 93.790
Low
112.00
Averages
125.74
High
140.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
This Successful Fund Manager Favors J&J, Lowe’s, and Utility Stocks
- Active Equity Managers: Few active equity managers consistently outperform the S&P 500 index.
- Long-Term Consistency: It is even rarer for these managers to achieve consistent success over many years.
Continue Reading
Boston Scientific Faces Setback; Acquisition of Penumbra Expected to Boost Stock Performance.
- Acquisition Focus: Boston Scientific is heavily focused on acquisitions as part of its growth strategy.
- Stock Impact: The latest acquisition has negatively affected the company's stock in the short term, but it is expected to yield positive results in the future.
- Investor Patience: Investors are encouraged to remain patient as the long-term benefits of the acquisition are anticipated to materialize.
- Future Outlook: Despite current stock challenges, the outlook for Boston Scientific remains optimistic due to its strategic acquisitions.
Continue Reading